Taipei Exchange - Delayed Quote TWD

Orient Pharma Co., Ltd. (4166.TWO)

32.75
-0.25
(-0.76%)
As of 11:22:00 AM GMT+8. Market Open.
Loading Chart for 4166.TWO
  • Previous Close 33.00
  • Open 34.00
  • Bid 32.45 x --
  • Ask 32.75 x --
  • Day's Range 32.40 - 34.00
  • 52 Week Range 24.85 - 50.70
  • Volume 50,277
  • Avg. Volume 81,146
  • Market Cap (intraday) 7.304B
  • Beta (5Y Monthly) -0.13
  • PE Ratio (TTM) 60.65
  • EPS (TTM) 0.54
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Orient Pharma Co., Ltd. engages in the research and development, manufacturing, and sales of drugs in Taiwan and internationally. The company develops anti-psychotics and psychostimulants, as well as drugs for treating Parkinson's and Alzheimer's diseases; and products for the treatment of sialorrhea, tuberculosis, and attention deficit hyperactivity disorder. It is also developing drug delivery technologies, such as multi-stages-controlled release technology, trans-dermal patches, oral disintegrating tablets, sustained release technology, and micro granules. The company was founded in 2008 and is based in Taipei, Taiwan.

www.oppharma.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4166.TWO

View More

Performance Overview: 4166.TWO

Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4166.TWO
8.77%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
5.45%

1-Year Return

4166.TWO
24.52%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
2.99%

3-Year Return

4166.TWO
64.57%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
37.57%

5-Year Return

4166.TWO
146.24%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
101.39%

Compare To: 4166.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4166.TWO

View More

Valuation Measures

Annual
As of 5/14/2025
  • Market Cap

    7.36B

  • Enterprise Value

    7.68B

  • Trailing P/E

    61.11

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.82

  • Price/Book (mrq)

    4.00

  • Enterprise Value/Revenue

    6.07

  • Enterprise Value/EBITDA

    23.48

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.78%

  • Return on Assets (ttm)

    3.88%

  • Return on Equity (ttm)

    6.21%

  • Revenue (ttm)

    1.22B

  • Net Income Avi to Common (ttm)

    107.37M

  • Diluted EPS (ttm)

    0.54

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    109.3M

  • Total Debt/Equity (mrq)

    30.57%

  • Levered Free Cash Flow (ttm)

    96.9M

Research Analysis: 4166.TWO

View More

Company Insights: 4166.TWO

Research Reports: 4166.TWO

View More

People Also Watch